RxDoctor Payments Data

Kimberly Gray-White, MD

Family Medicine · Tampa, FLNPI 1598783193

Payments from drug & device makers

$762in general payments, 2019–2025

Across 32 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$195
  • AstraZeneca$125
  • Amgen$105
  • Ultragenyx Pharmaceutical Inc.$42
  • Vanda Pharmaceuticals Inc.$42
  • Mylan Specialty L.p.$41
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$75399%
  • Education$81%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$762 in reported general payments places this provider in the 60th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$3,398
Medicare patients
15
Services billed
32

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban105$67,889
JardianceEmpagliflozin16$9,247
Novolin 70-30Insulin Nph Hum/Reg Insulin Hm45$8,676
Sucralfate13$4,804
Losartan Potassium367$3,279
Atorvastatin Calcium466$3,229
Fluticasone-SalmeterolFluticasone Propion/Salmeterol30$3,135
Gabapentin243$3,099
Lantus SolostarInsulin Glargine,hum.Rec.Anlog22$3,099
Potassium Chloride195$2,868
Fluticasone Propionate295$2,740
Levothyroxine Sodium201$2,202
Novolin 70-30 FlexpenInsulin Nph Hum/Reg Insulin Hm15$2,129
Albuterol Sulfate HfaAlbuterol Sulfate63$1,892
Montelukast Sodium246$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$41$67,889105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →